Loading...
Market
Story
India to Introduce PLI Scheme for Domestic Manufacturing of GLP-1 Drugs for Diabetes and Obesity in 2026
Jun 28, 2024, 08:33 AM
The Indian government is set to introduce a production-linked incentive (PLI) scheme in 2026 aimed at promoting the domestic manufacturing of GLP-1 drugs. These drugs are primarily used in the treatment of diabetes and obesity. The initiative is part of a broader effort to boost local pharmaceutical manufacturing and reduce dependency on imports. A government official confirmed the plan, highlighting its potential impact on the healthcare sector in India. The PLI scheme specifically targets the production of drugs used for obesity and diabetes.
View original story
Similar markets
Novo Nordisk • 25%
Eli Lilly • 25%
Pfizer • 25%
Other • 25%
Novo Nordisk • 25%
Sanofi • 25%
Merck • 25%
Other • 25%
Novo Nordisk • 25%
Eli Lilly • 25%
AstraZeneca • 25%
Other • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Roche • 25%
Other • 25%
Pfizer • 25%
Merck • 25%
Johnson & Johnson • 25%
Other • 25%
None • 25%
1 company • 25%
2 companies • 25%
3 or more companies • 25%
Wegovy • 25%
Zepbound • 25%
Ozempic • 25%
Other • 25%
Eli Lilly • 25%
Novo Nordisk • 25%
Pfizer • 25%
Other • 25%
Pfizer • 25%
Roche • 25%
Johnson & Johnson • 25%
Novartis • 25%
Novo Nordisk • 25%
Sanofi • 25%
Eli Lilly • 25%
Other • 25%
